Opinion|Videos|September 10, 2024
Administering GPRC5D therapy: Dosing and Monitoring for CRS & ICANS
Author(s)Larysa Sanchez, MD, Samantha Shenoy, MSN, NP
Experts explain the administration of step-up and treatment doses for GPRC5D at your institution, including whether they are given in clinic or in the community, and will discuss how patients are monitored for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome during the step-up phase.
Advertisement
Episodes in this series
Video content above is prompted by the following:
How are the step-up and treatment doses for GPRC5D administered at your institution? Are they administered in your clinic or in the community?
- How are patients monitored for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome during step-up dosing?
Advertisement
Related to this article
Ramy Sedhom, MD, of Penn Medicine Princeton Health discusses blending palliative care with psycho-oncology to treat patient distress in oncology care.
FDA approves imlunestrant plus abemaciclib for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
At WCLC 2026, Kaitlyn Gregory details key oncology nursing insights into exercise, caregiver stress, screening models, and APP-led supportive care.
For Gynecologic Cancer Awareness Month, Dr. Eleonora Teplinsky outlines emerging treatment toxicities, patient advocacy, and health equity.
FDA approves sNDA for taletrectinib (Ibtrozi) in ROS1+ NSCLC with updated DOR of nearly 50 months.
Gigi Jameel, APRN, discusses supportive care interventions, ADT toxicity management, and team collaboration in prostate cancer care.
Patients often use AI to read test results, but AI can misinterpret data and cause panic. Learn why human context remains critical.
Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinical trials and nursing impacts of on-body isatuximab delivery in multiple myeloma.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Palliative and Psycho-Oncology Care: Dr. Ramy Sedhom on Patient Distress Signs
2
WCLC 2026: Oncology Nursing Takeaways on Supportive Care and APP-Led Models
3
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated, ER-Positive, HER2-Negative Advanced Breast Cancer
4
Recognizing and Evaluating Diarrhea in Metastatic Triple-Negative Breast Cancer
5